Market access management by pharmaceutical companies in a complex environment: The Italian case study

Journal of Medical Marketing

Volumn 12, Issue 2, 2012, Pages 93-103

  Jommi, Claudio ^a   Otto, Monica ^b   Armeni, Patrizio ^b   De Luca, Clea ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

Author keywords

market access; organization; Pharmaceuticals; policy; strategy

Indexed keywords

EID: 84873619643     PISSN: 17457904     EISSN: 17457912     Source Type: Journal    
DOI: 10.1177/1745790412440704     Document Type: Article

References (28)

1. Fattore G, Jommi C. The Last decade of Italian pharmaceutical policy: instability or consolidation?. Pharmacoeconomics. 2008 ; 26: 5-15
2. Folino Gallo P, Montilla S, Bruzzone M, et al. Pricing and reimbursement of pharmaceuticals in Italy. Eur J Health Econ. 2008 ; 9: 305-310
3. EFPIA. Market Access Delays, http://www.efpia.org/content/default.asp? PageID=610 (2010, accessed 15 October 2011).
4. Department of Health, The Pharmaceutical Price Regulation Scheme: Tenth Report to Parliament, December 2009, (available at: www.parliament.uk/deposits/ depositedpapers/2009/DEP2009-3123.pdf, accessed 5 October 2011).
5. Russo P, Mennini FS, Siviero PD, et al. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol. 2010 ; 21: 2081-2087
6. Compagni A, Cavalli L, Jommi C. Pharmaceutical companies and Italian Regional Governments: managing relationships in an increasing institutional complexity. Health Policy. 2008 ; 87: 333-341
7. Montoya-Weiss M, Calantone R. Determinants of new product performance: a review and meta-analysis. J Prod Innovation Manage. 1994 ; 11: 397-417
8. Matrave C. Market structure, R&D and advertising in the pharmaceutical industry. J Ind Econ. 1999 ; 47: 169-194
9. Hagedoorn J. Understanding the rationale of strategic technology partnering: interorganizational modes of cooperation and sectoral differences. Strategic Manage J. 1993 ; 14: 371-385
10. Sivadas E, Dwyer FR. An examination of organizational factors influencing new product success in internal and alliance-based processes. J Market. 2000 ; 64: 31-49
11. Kale P, Dyer JH, Singh H. Alliance capability, stock market response, and long term alliance success: the role of the alliance function. Strategic Manage J. 2002 ; 23: 747-767
12. Heiduk G. Multinationalization in the pharmaceutical industry as a response to national health policies. Manag Decision Econ. 1982 ; 3: 194-204
13. Chao RO, Kavadias S. A Theoretical framework for managing the new product development portfolio: when and how to use strategic buckets. Manage Sci. 2008 ; 54: 907-921
14. Yeoh P. Speed to global markets: an empirical prediction of new product success in the ethical pharmaceutical industry. Eur J Market. 1994 ; 28: 29-49
15. Pan Y, Li S, Tse DK. The impact of order and mode of market entry on profitability and market share. J Int Bus Stud. 1999 ; 30: 81-103
16. Trim P, Pan H. A new product launch strategy (NPLS) model for pharmaceutical companies. Eur Bus Rev. 2005 ; 17: 325-339
17. Poh-Lin Y, Roth K. An empirical analysis of sustained advantage in the U.S. pharmaceutical industry: impact of firm. Strategic Manage J. 1999 ; 20: 637-653
18. Dierickx I, Cool K. Asset stock accumulation and the sustainability of competitive advantage: reply. Manage Sci. 1989 ; 35: 1514-1515
19. Lado AA, Boyd NG, Wright PA. Competency-based model of sustainable competitive advantage: toward a conceptual integration. J Manage. 1992 ; 18: 77-77
20. Leonard-Barton D. Core capabilities and core rigidities: a paradox in managing new product development. Strategic Manage J. 1992 ; 13: 111-125
21. Pattikawa LH, Verwaal E, Commandeur HR. Understanding new product project performance. Eur J Market. 2006 ; 40: 1178-1193
22. Babbie E The practice of social research. 5 th ed. Belmont, CA: Wadsworth, 1989. Belmont, CA: Wadsworth ; 1989 :
23. Wang L. Ownership, size, and the formal structure of organizations: evidence from US public and private firms, 1992-2002. Ind Corp Change. 2009 ; 18: 595-636
24. Dillman DA Mail and Internet surveys: the tailored design method. 2 nd ed. New York: John Wiley and Sons, 2000. New York: John Wiley and Sons ; 2000 :
25. McCabe CJ, Stafinski T, Edlin R, et al. Access with evidence development schemes. Pharmacoeconomics. 2010 ; 28: 143-152
26. Carlson JJ, Sullivan SD, Garrison LP, et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010 ; 96: 179-190
27. Pharmacetical Observatory CB. Executive Summary Report 26, http://portaleunibocconi.it/wps/wcm/connect/Centro-CERGASit/Home/Chi+siamo/ Osservatori/OSFAR/Report/ (2011, accessed 2 October 2011).
28. AIOM, CENSIS, FAVO. Secondo Rapporto sulla Condizione Assistenziale dei malati oncologici, http://www.perunavitacomeprima.org/public/immagini/file/ secondo-rapporto-favo-censis.pdf (2010, accessed 2 October 2011).